Onco-Innovations Advances PNKP Inhibitor Manufacturing Scale-Up with Dalton Pharma for Phase 1 Clinical Trials
核心洞察
Onco-Innovations has initiated process optimization and intermediate scale-up activities for A83B4C63 (搜索), its proprietary PNKP (搜索) inhibitor technology, with manufacturing partner Dalton Pharma Services (搜索).
The scale-up phase targets production of approximately 500g of precursor A83 and 1,000g of precursor B4 to evaluate reaction performance under scaled conditions.
The A83B4C63 (搜索) API will support development of an encapsulated nanoparticle micelle formulation designed to enhance tumor-targeted delivery and improve therapeutic efficacy in cancer treatment.
Onco-Innovations Limited (搜索) has announced a significant advancement in the development of its proprietary PNKP (搜索) inhibitor technology, with manufacturing partner Dalton Pharma Services (搜索) initiating process optimization and intermediate scale-up activities for A83B4C63 (搜索). This development marks a crucial step toward preparing the compound for future Phase 1 clinical trials.
Manufacturing Scale-Up Initiative
Building on previous manufacturing activities initiated by Dalton for preclinical testing material in May 2025, the company has now progressed to optimization and intermediate-scale production of A83B4C63 (搜索) for research purposes. The current phase focuses on process scale-up and analytical method qualification to ensure a robust, reproducible, and scalable manufacturing process suitable for future GMP production.
The work is being conducted using dedicated pilot-scale equipment at Dalton's FDA- and Health Canada-approved facility in Toronto, Canada. As part of this optimization phase, Dalton will conduct intermediary scale-up batches targeting approximately 500g of precursor A83 and 1,000g of precursor B4 to evaluate reaction performance under scale-up conditions in preparation for pre-clinical production of A83B4C63 (搜索).
Novel Drug Delivery Technology
The A83B4C63 (搜索) active pharmaceutical ingredient will be used to support the development of Onco's encapsulated nanoparticle micelle formulation. This innovative delivery system is designed with the goal of enhancing tumor-targeted delivery of the PNKP (搜索) inhibitor, with the ultimate objective of potentially improving therapeutic efficacy in cancer treatment.
Comprehensive Development Program
The manufacturing program includes comprehensive analytical method development and stability testing conducted in accordance with International Council for Harmonisation (ICH) guidelines. Additionally, a formal safety and risk assessment of A83B4C63 (搜索) will be conducted prior to full-scale synthesis. The optimization work encompasses precursor synthesis refinement, process scale-up, and analytical method development in accordance with international quality standards.
"This milestone marks a pivotal transition from lab-scale synthesis to scalable pre-clinical manufacturing of our lead PNKP (搜索) inhibitor," said Thomas O'Shaughnessy, Chief Executive Officer of Onco-Innovations. "Dalton's deep expertise and regulatory credentials make them an ideal partner as we continue to move towards clinical development. This phase is intended to lay the groundwork for meeting the rigorous standards required for future GMP production and clinical trial readiness."
Strategic Partnership
Dalton Pharma Services (搜索), established in 1986 and based in Toronto, Canada, is a Health Canada-approved and FDA-inspected GMP contract provider of integrated chemistry, drug development, and manufacturing services. With over 35 years of experience, Dalton offers comprehensive in-house services including drug discovery, flow chemistry, formulation and process development, custom synthesis, cGMP sterile fill/finish, cGMP API manufacturing, and dosage form manufacturing.
Clinical Development Pathway
The current manufacturing development program is designed to support Onco's IND enabling studies and subsequent Phase 1 clinical trials. Onco-Innovations, a Canadian-based company dedicated to cancer research and treatment, has secured an exclusive worldwide license to patented technology that targets solid tumors. The company's mission focuses on pursuing the prevention and treatment of cancer through pioneering research and innovative solutions.